en · de · es · fr · pt
melanotan-2-notes.peptides9002.com › Topic › Peptide Identity And Structural Background — 2026 Update

Peptide Identity And Structural Background — 2026 Update

By Editorial Desk · published 2026-07-21 · last reviewed 2026-08-01 · Topic

The short version of cyclic heptapeptide fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.

Peptide Identity and Structural Background

The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.

Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.

Chemistry and Receptor Pharmacology

Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.

Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Synthetic cyclic heptapeptide
Molecular massApproximately 1024 g/molDepends on counter-ion content
AppearanceWhite to off-white powderCommonly supplied as a lyophilised solid
SolubilityFreely soluble in waterAlso dissolves in common aqueous buffers
Typical storage-20 degrees Celsius, desiccatedProtect from light and repeated freeze-thaw

Background and Receptor Mechanism

Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.

Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.

Related pages on this site

Melanotan-2 Identity and Receptor Pharmacology

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.

Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.

Further detail

== Epidemiology == The prevalence of GDM was 14.7%, 9.9%, and 14.4% in low-income countries (LIC), middle-income countries (MIC), and high-income countries (HIC) in 2021 by the International Association of Diabetes in Pregnancy Study Group's criteria. By 2021, the Global prevalence of hyperglycemia in pregnancy (HIP) as per the IDF atlas will be 21.1 million people, accounting for 16.7% of births to women aged 20-49. These individuals may experience some form of hyperglycemia during pregnancy; 80.3% of these were due to GDM.

=== Actin binding proteins === The actin cytoskeleton in vivo is not exclusively composed of actin, other proteins are required for its formation, continuance, and function. These proteins are called actin-binding proteins and they are involved in actin's polymerization, depolymerization, stability, and organisation. The diversity of these proteins is such that actin is thought to be the protein that takes part in the greatest number of protein–protein interactions.

=== Repurposing for hair growth === When Upjohn received permission from the U.S. Food and Drug Administration (FDA) to test the new drug as medicine for hypertension they approached Charles A. Chidsey, at the University of Colorado School of Medicine. He conducted two studies, the second study showing unexpected hair growth. Puzzled by this side-effect, Chidsey consulted Guinter Kahn (who while a dermatology resident at the University of Miami had been the first to observe and report hair development on patients using the minoxidil patch) and discussed the possibility of using minoxidil for treating hair loss. Kahn, along with his colleague Paul J. Grant, had obtained a certain amount of minoxidil and conducted their own research, since they were first to make the side effect observation. Neither Upjohn or Chidsey at the time were aware of the side effect of hair growth. The two doctors had been experimenting with a 1% solution of minoxidil mixed with several alcohol-based liquids. Both parties filed patents to use minoxidil for hair loss prevention, which resulted in a decade-long trial between Kahn and Upjohn, which ended with Kahn's name included in a consolidated patent (U.S. #4,596,812 Charles A Chidsey, III and Guinter Kahn) in 1986 and royalties from the company to both Kahn and Grant. Meanwhile, the effect of minoxidil on hair loss prevention was so clear that in the 1980s physicians were prescribing Loniten off-label to their balding patients.

The three substrates of this enzyme are artemisinic aldehyde, reduced nicotinamide adenine dinucleotide phosphate (NADPH), and a proton. Its products are (11R)-dihydroartemisinic aldehyde and oxidised NADP+. This enzyme is present in Artemisia annua.

== Organisation structure == The ARL is governed by a board of directors, referred to as a “commission”. The board was previously composed of representatives of member clubs and state leagues but was reconstituted with directors independent of the member clubs and leagues and renamed as a “commission”. It is headquartered in Sydney at “Rugby League Central”, Moore Park, New South Wales. All 17 National Rugby League clubs and the New South Wales Rugby League and the Queensland Rugby League are members of the commission. This means that the commission has 19 shareholder members in total.

Sources: en.wikipedia.org

Supporting material

In 2011, a randomized controlled trial with 740 patients found cytisine improved 12-month abstinence from nicotine from 2.4% with placebo to 8.4% with cytisine. A 2013 meta-analysis of eight studies demonstrated that cytisine has similar effectiveness to varenicline but with substantially lower side effects. A 2014 systematic review and economic evaluation concluded that cytisine was more likely to be cost-effective for smoking cessation than varenicline. It is on the World Health Organization's List of Essential Medicines.

Not moving or speaking (stupor or mutism) Unusual body positions Repeating words or actions Sudden restlessness Other, less common symptoms The DSM-5 and ICD-11, global manuals for mental health conditions, describe catatonia and its various types. Catatonia can occur with other mental illnesses, like depression or schizophrenia. It may also be a reaction to certain drugs or a medical condition. While often linked to psychiatric disorders, about one in five cases of catatonia are due to medical conditions. There is not a definitive consensus regarding diagnostic criteria. In the fifth edition of the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-5, 2013) and the eleventh edition of the World Health Organization's International Classification of Diseases (ICD-11, 2022), the classification is more homogeneous than in earlier editions. Prominent researchers in the field have other suggestions for diagnostic criteria. Still, diagnosing catatonia can be challenging. Evidence suggests that there is as high as a 15-day average delay to diagnosis for people with catatonia.

=== United States plan === Immediate ceasefire: An immediate end to hostilities between the US (and Israel) and Iran. Two-phase agreement structure: Reopening the Strait of Hormuz: Iran must immediately reopen the Strait of Hormuz, restoring global oil flow. Guaranteed maritime security: Creating a regional framework ensuring safe navigation through the Strait of Hormuz. Nuclear constraints on Iran: Iran commits to stop its alleged pursuit of nuclear weapons as part of the final deal Sanctions relief (conditional): The US signaled willingness to ease sanctions, but only in exchange for Iranian concessions. Release of frozen Iranian assets: Part of incentives included unfreezing Iranian funds abroad Structured negotiations via mediators: All talks will be channeled through Pakistan initially, then finalized in Islamabad. Possible extended ceasefire window: During Phase 2 the discussions will be over a period of 45 days. Broader regional de-escalation: The agreement aims to stabilize additional conflicts in the Middle East, not just the war with Iran.

=== Types === The ABO blood group system was discovered in the year 1900 by Karl Landsteiner. Jan Janský is credited with the first classification of blood into the four types (A, B, AB, and O) in 1907, which remains in use today. In 1907 the first blood transfusion was performed that used the ABO system to predict compatibility. The first non-direct transfusion was performed on 27 March 1914. The Rhesus factor was discovered in 1937.

Sources: en.wikipedia.org

Supporting material

The "Venus" figurines have been theorized, not universally, as representing a mother goddess; the abundance of such female imagery has inspired the theory that religion and society in Paleolithic (and later Neolithic) cultures were primarily interested in, and may have been directed by, women. Adherents of the theory include archaeologist Marija Gimbutas and feminist scholar Merlin Stone, the author of the 1976 book When God Was a Woman. Other explanations for the purpose of the figurines have been proposed, such as Catherine McCoid and LeRoy McDermott's hypothesis that they were self-portraits of woman artists and R.Dale Gutrie's hypothesis that served as "Stone Age pornography".

A number of studies has now demonstrated that aqueous exposure to components within the UCM can affect the health of marine organisms, including possible hormonal disruption, and high concentrations of environmental UCMs have been strongly implicated with impaired health in wild populations.

Following three constitutional conferences, the British North America Act, 1867 officially proclaimed Canadian Confederation on July 1, 1867, initially with four provinces: Ontario, Quebec, Nova Scotia, and New Brunswick. Canada assumed control of Rupert's Land and the North-Western Territory to form the Northwest Territories, where the Métis' grievances ignited the Red River Rebellion and the creation of the province of Manitoba in July 1870. British Columbia and Vancouver Island (which had been united in 1866) joined the confederation in 1871 on the promise of a transcontinental railway extending to Victoria in the province within 10 years, while Prince Edward Island joined in 1873. In 1898, during the Klondike Gold Rush in the Northwest Territories, Parliament created the Yukon Territory. Alberta and Saskatchewan became provinces in 1905. Between 1871 and 1896, almost one quarter of the Canadian population emigrated south to the US. To settle the West and attract European immigrants, Canada sponsored the construction of three transcontinental railways, enacted the Dominion Lands Act and founded the North-West Mounted Police to maintain regional authority. This period of westward expansion and nation building resulted in the displacement of many Indigenous peoples of the Canadian Prairies to "Indian reserves", clearing the way for ethnic European block settlements. This caused the collapse of the Plains Bison in western Canada and the introduction of European cattle farms and wheat fields dominating the land.

Sources: en.wikipedia.org

Frequently asked questions

What is Melanotan-2 chemically?

It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.

How does it differ from the natural hormone?

It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.

When was Melanotan-2 first described?

Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.

Is melanotan II identical to alpha-melanocyte-stimulating hormone?

No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.

Network